中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

科学论文
SCIENTIFIC PUBLICATION
  • 04.182025
    2024
    Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune responseNat Commun. 2024 Oct 3;15:8569. doi: 10.1038/s41467-024-52902-5Tan L, Yin T, Xiang H, Wang L, Mudgal P, Chen J, Ding Y, Wang G, Lim BJW, Huang Y, Huang D,
  • 04.162025
    2023
    A prognostic model of drug tolerant persister-related genes in lung adenocarcinoma based on single cell and bulk RNA sequencing dataHeliyon. 2023 Oct 5;9(11):e20708. doi: 10.1016/j.heliyon.2023.e20708Du Z, Zhang T, Lin Y, Dong G, Li A, Wang Z, Zhang
  • 06.142022
    2022
    Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. Cancer Cell 40, 674-693, June 13, 2022 doi:https://doi.org/10.1016/j.ccell.2022.04.018Haixia Long, Qingzhu Jia
  • 03.232022
    2021
    Cancer Cell-Derived GABA Promotes β-Catenin-Mediated Tumor Growth and Immunosuppression.Nat Cell Biol. Author manuscript; available in PMC: 2022 Aug 10.Published in final edited form as: Nat Cell Biol. 2022 Feb 10;24(2):230–241. do
  • 03.232022
    2020
    Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. OncoImmunology 9(1):1806009. (*: Corresponding authors, PMCID: PMC7458607)Qin D., Li D., Zhang B., Chen Y., Liao X., Li X., Alexander P.B., W
  • 03.232022
    2019
    Streamlined Low-Input Transcriptomics through EASY-RNAseq. J Mol Biol. 431(24):5075-5085. (PMID: 31491452)Zhou Y., Xu H., Wu H., Yu H., Zhou P., Qiu X., Zheng Z., Chen Q., Xu F., Li G., Zhou J., Cheng G., He W., Zou L, Wan Y. (2019) TCR repertoi
12
查看更多

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer